1. Use of oral and transdermal opioids among patients with metastatic cancer during the last year of life 
Ariel Berger, MPH, Ellen Dukes, PhD, RN, Meredith Smith, PhD, May Hagiwara, PhD, Raafat Seifeldin, PharmD, PhD, Gerry Oster, PhD 
Journal of Pain and Symptom Management 
Volume 26, Issue 2, Pages (August 2003)
DOI: /S (03)

2. Fig. 1
Percentage of patients with metastatic cancer receiving any opioids, by presence of bone metastases and one month prior to death.
Journal of Pain and Symptom Management  , DOI: ( /S (03) )

3. Fig. 2.
Percentage of patients with metastatic cancer receiving long-acting opioids, by presence of bone metastases and month prior to death.
Journal of Pain and Symptom Management  , DOI: ( /S (03) )

4. Fig. 3.
Percentage of noninstitutionalized days on which patients with metastatic cancer received any opioids, by presence of bone metastases and month prior to death.
Journal of Pain and Symptom Management  , DOI: ( /S (03) )

5. Fig. 4.
Percentage of noninstitutionalized days on which patients with metastatic cancer received long-acting opioids, by presence of bone metastases and month prior to death.
Journal of Pain and Symptom Management  , DOI: ( /S (03) )